Evidence map›Paper›PMID 35478773›Full record

ArticleOncotarget2022

Bladder cancer survival in patients with

Elżbieta Złowocka-Perłowska, Thierry van de Wetering, Aleksandra Tołoczko-Grabarek, Rodney J Scott, Jan Lubiński

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Elżbieta Złowocka-PerłowskaDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Thierry van de WeteringDepartment of Clinical and Molecular Biochemistry, Pomeranian Medical University, Szczecin, Poland.
Aleksandra Tołoczko-GrabarekDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Rodney J ScottSchool of Biomedical Sciences and Pharmacy, Centre for Information-Based Medicine, Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW 2305, Australia.
Jan LubińskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Pomeranian Medical University · PLHunter Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe association between the MATERIALS AND

methodsWe compared the allele frequencies of

resultsAmong the three patient subgroups: patients under 60 years of age, non-smokers and a third with histological features of low grade noninvasive papillary bladder cancer, we observed that the c.3020insC allele had a nominal statistically significant effect on survival. We also observed that the

conclusionWe have shown that the

Indexed as

Kidney NeoplasmsUrinary Bladder NeoplasmsAgedCyclin-Dependent Kinase Inhibitor p16Genetic Predisposition to DiseaseHumansMiddle AgedNod2 Signaling Adaptor ProteinUrinary BladderCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16NOD2 protein, humanNod2 Signaling Adaptor Proteinbladder cancerCDKN2Akidney cancerNOD2survival

Identifiers

PMID35478773
PMCPMC9037518
OpenAlexW4224326527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.